Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update

Arbutus Biopharma Co. (NASDAQ:ABUS) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 5,370,000 shares, an increase of 6.8% from the May 31st total of 5,030,000 shares. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is presently 4.2 days.

Wall Street Analyst Weigh In

ABUS has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Thursday, June 6th. JMP Securities restated a “market outperform” rating and set a $4.00 target price on shares of Arbutus Biopharma in a research report on Thursday, April 4th. Finally, Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of Arbutus Biopharma in a research report on Wednesday, June 5th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Walleye Trading LLC bought a new position in shares of Arbutus Biopharma in the first quarter worth about $36,000. PFG Investments LLC bought a new position in shares of Arbutus Biopharma in the first quarter worth about $50,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Arbutus Biopharma by 351.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 15,104 shares during the last quarter. Premier Path Wealth Partners LLC bought a new position in shares of Arbutus Biopharma in the fourth quarter worth about $56,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Arbutus Biopharma by 22.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 6,649 shares during the last quarter. 43.79% of the stock is currently owned by institutional investors.

Arbutus Biopharma Stock Up 1.0 %

ABUS stock opened at $3.12 on Tuesday. Arbutus Biopharma has a twelve month low of $1.69 and a twelve month high of $3.64. The stock has a market capitalization of $588.80 million, a price-to-earnings ratio of -7.09 and a beta of 1.98. The firm’s fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $2.76.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $2.16 million. Arbutus Biopharma had a negative net margin of 572.81% and a negative return on equity of 62.68%. As a group, equities research analysts expect that Arbutus Biopharma will post -0.39 EPS for the current year.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.